TORONTO, ONTARIO--(Marketwire - Oct. 23, 2012) -
Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), announced today that it has successfully completed the first commercial installation of Visualize:Vascular™ in a key new market in the US. Visualize:Vascular™ has been integrated into the standard protocols for carotid scanning of VascuCare™, a premiere vascular ultrasound services provider in Northern California, operating with full Intersocietal Accreditation Commission (IAC) certification.
"Our vascular technologists and physician partners use state of the art technologies to obtain consistent, reproducible results. We wanted to see the benefit of Visualize:Vascular's 3D rendering in our vascular labs and we are delighted with the results," commented Brad Hummel, CEO of VascuCare. "Visualize is clinically relevant, easy to use and provides an additional source of revenue. Our physicians find that the 3D is tremendously helpful in tough cases. Our technologists just add a simple 10 second scan to their normal procedure and the 3D report is available quickly and conveniently for the physicians to review."
"VascuCare provides the services of superior technologists in the vascular labs of many facilities including four hospitals and two outpatient clinics. Their staff performs over 15,000 vascular ultrasound procedures per year," commented Jeff Collins, CEO of Medipattern. "VascuCare is a strategic partner on the further United States (US) rollout for Visualize:Vascular. Medipattern has been targeting vascular ultrasound providers, such as in-facility providers and our recently announced focus on mobile providers, which can facilitate penetrating the US market as we intensify our adoption phase. Ultrasound providers, such as VascuCare, use our products throughout their installed base with their end user customers providing Medipattern more visibility and to roll out our products more rapidly. California is a strategic target market for any company wishing to establish itself on the west coast of the US. We appreciate the opportunity to work with VascuCare in opening up the California market."
VascuCare is operated by HDultrasound which was founded in 1999. VascuCare provides high quality non-invasive vascular lab services throughout Northern California including Alameda County Medical Center, Highland Hospital, Kaiser Santa Clara, and Kaiser South San Francisco. For more information, please visit www.vascucare.net.
About the Medipattern Corporation:
Medipattern® is an award-winning leader in the development and commercialization of healthcare solutions that positively impact people's lives through the prevention of disease and analysis of medical images and data. Medipattern's Knowledge-based Informatics (MKI) platform enables delivery of these streamlined solutions. Medipattern mHealth uses patented prevention technologies to engage, coach and monitor people in achieving their personalized goals. Medipattern iaHealth uses patented pattern recognition technology to analyze medical data to aid medical practitioners in the assessment of disease and critical anatomy. For more information, please visit the Company's website: www.medipattern.com.
Medipattern® is registered trademarks of The Medipattern Corporation. Visualize:Vascular™ is a registered trademark of Medipattern.
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). These factors should be considered carefully, and readers should not place undue reliance on Medipattern's forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.